Payment overview · 2025
General Payments
$265.03
14 reported records · 6 companies
Healthcare provider profile · identity verified
Dennis Conrad Harper, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DOUGLAS, GA · NPI 1043203425
Verified facts
What the public records show
CMS Open Payments records show Dennis Conrad Harper, M.D. received $265.03 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.56 | 31.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.84 | 26.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.18 | 18.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.18 | 10.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.84 | 6.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.43 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.03 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.56 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.84 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.19 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1117 | 132 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 476 | 59 |
| Alprazolam | Alprazolam | 290 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 95 |
| Gabapentin | Gabapentin | 259 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 78 |
| Meloxicam | Meloxicam | 195 | 49 |
| Furosemide | Furosemide | 188 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 55 |
| Allopurinol | Allopurinol | 131 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 41 |
| Metformin Hcl | Metformin Hcl | 126 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 13 |
| Potassium Chloride | Potassium Chloride | 121 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 36 |
| Montelukast Sodium | Montelukast Sodium | 109 | 41 |
| Tramadol Hcl | Tramadol Hcl | 107 | 30 |
| Omeprazole | Omeprazole | 105 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 37 |
| Lisinopril | Lisinopril | 98 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 29 |
| Simvastatin | Simvastatin | 95 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 28 |
| Doxepin Hcl | Doxepin Hcl | 86 | 14 |
| Carvedilol | Carvedilol | 80 | 30 |
| Lorazepam | Lorazepam | 80 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 30 |
| Mounjaro | Tirzepatide | 77 | 27 |
| Famotidine | Famotidine | 74 | 30 |
| Losartan Potassium | Losartan Potassium | 72 | 28 |
| Clonidine Hcl | Clonidine Hcl | 70 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 16 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Eliquis | Apixaban | 65 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 20 |
| Ezetimibe | Ezetimibe | 57 | 23 |
| Celecoxib | Celecoxib | 56 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 11 |
| Methadone Hcl | Methadone Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Linzess | Linaclotide | 42 | 12 |
| Fentanyl | Fentanyl | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Pregabalin | Pregabalin | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Ozempic | Semaglutide | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Glipizide | Glipizide | 21 | 12 |
| Baclofen | Baclofen | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Ramipril | Ramipril | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.03 · 14 records | GlaxoSmithKline, LLC. | AREXVY, INSPIRE, OTEZLA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error